Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.45 |
| ▸ | SGK1 | O00141 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 11/20 | 0.44 |
| ▸ | ITK | Q08881 | 11/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564788 | 1.00 | AXL (0.45) | AXLSGK1CAMKK2NAPRTBTK | |
| SCHEMBL17786923 | 0.85 | ITK (0.45) | AXLCAMKK2BTKITKACACB | |
| SCHEMBL4397837 | 0.81 | BTK (0.45) | SGK1BTKITKACACBACACA | |
| SCHEMBL30731289 | 0.80 | AXL (0.45) | AXLSGK1CAMKK2NAPRTITK | |
| SCHEMBL22554109 | 0.80 | AXL (0.45) | AXLSGK1CAMKK2NAPRTITK | |
| SCHEMBL20292915 | 0.80 | AXL (0.48) | AXLSGK1CAMKK2ITK | |
| SCHEMBL20319065 | 0.80 | AXL (0.45) | AXLSGK1CAMKK2BTKITK | |
| SCHEMBL13387062 | 0.78 | AXL (0.44) | AXLSGK1CAMKK2ITK | |
| SCHEMBL22578328 | 0.76 | AXL (0.42) | AXLSGK1CAMKK2ITK | |
| SCHEMBL29958524 | 0.76 | BTK (0.44) | SGK1BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | MYOFORTE THERAPEUTICS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| CN-103189377-A | N1/n2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2013-07-03 | — | — | CN | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | AXL 4865/4885SGK1 2119/4885CAMKK2 1702/4885 |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | AXL 4877/4885SGK1 2483/4885CAMKK2 2342/4885 |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | AXL 4877/4885SGK1 2483/4885CAMKK2 2342/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | AXL 4865/4885SGK1 2119/4885CAMKK2 1702/4885 |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | HPGD, HPGDS, GCDH | AXL 4582/4885SGK1 3924/4885CAMKK2 4092/4885 |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | AXL 4877/4885SGK1 2483/4885CAMKK2 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.